New Mass Cytometry Dataset Detects Immune Signatures of Clinical Activity of bintrafusp alfa (BA) in patients with advanced non-small cell lung cancer (NSCLC)

We're making available a 44-marker mass cytometry dataset we generated from 35 PBMC specimens collected across 12 NSCLC patients at the National Cancer Institute (NCI). This dataset was the foundation of a 2023 ASCO poster co-led by us and colleagues at the NCI, which investigated immune signatures of survival and clinical response in patients treated with BA, a bifunctional fusion protein targeting PD-L1 and TGF-β (NCT02517398).

Why this matters

When developing immunotherapies, translational teams depend on reliable biomarkers that can predict response and survival and explain drug MOA. With this dataset, the NCI team identified several immune subsets tied to treatment outcomes:

• Memory B cells were enriched in responders at baseline and again after three doses.
• CD16+ NK cells expanded after one dose in patients who achieved response or stable disease.
• T-bet+ double negative T cells (DNTs) tracked with clinical benefit after three doses.
• Conversely, higher baseline CD16+ NK cells were linked to shorter progression-free survival.
• DNTs and classical monocytes also associated with progression-free survival: higher CD161+CD127+ DNTs after one dose correlated with longer survival, while expansion of IgG4+PD-1+ monocytes after three doses correlated with shorter survival.

These findings demonstrate how high-dimensional mass cytometry can uncover immunological correlates of clinical activity, opening opportunities for biomarker-driven trial design and patient stratification.

Dataset Featured at ASCO 2023

The dataset supported the following work: “Mass cytometry immune profiling to detect signatures of clinical activity of bintrafusp alfa (BA) in patients with advanced non-small cell lung cancer (NSCLC)”

Available today!  

We’ve made this resource available so you can access real-world, high-dimensional immune profiling data that accelerates biomarker discovery and helps you make faster, more confident decisions.

Explore the dataset today:

‍ app.teiko.bio (NCI002)